Ferdows Atiq

Learn More
Cyclosporine A (CsA) and imatinib are both CYP3A4 and P-glycoprotein substrates. Concomitant use after hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (ALL) may therefore result in a pharmacokinetic interaction. Although case reports and a recent small study(More)
Although therapeutic dosages of most low-molecular-weight heparins (LMWHs) are known to accumulate in patients with renal insufficiency, for the lower prophylactic dosages this has not been clearly proven. Nevertheless, dose reduction is often recommended. We conducted a systematic review to investigate whether prophylactic dosages of LMWH accumulate in(More)
Dear Editor, We thank Dr. A.E. Eskazan for his comment on our recent article on the drug-drug interaction between cyclosporine A (CsA) and imatinib, in which he asked for some important clarifications [1]. The first question raised was why the patients were treated with imatinib after allogeneic hematopoietic stem cell transplantation (alloHSCT) instead of(More)
  • 1